Autologous bone marrow/stem cell transplantation: Initial experience at a north Indian referral centre

National Medical Journal of India

Volumn 13, Issue 2, 2000, Pages 61-66

  Gupta, S ^a   Kumar, L ^a   Raju, G M K ^a   Kochupillai, V ^a   Shukla, D K ^b  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDIA; LEUKEMIA; LYMPHOMA; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; RETROSPECTIVE STUDY; SURVIVAL;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDIA; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0034154857     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr. Increasing the therapeutic response rate to anticancer drugs by applying the basic principles of pharmacology. Cancer 1984;50 (Suppl 6):1160-7.
2. Frei E III, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
3. Brandwein JM, Callum J, Rubinger M, Scott JG, Keating A. An evaluation of outpatient bone marrow harvesting. J Clin Oncol 1989;7:648-50.
4. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
5. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-206.
6. BMDP Dynamic (Classic 7.0) Statistical Software. 1993.
7. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation: Development of an oral mucositis index. Cancer 1992;69: 2469-77.
8. Savarese DMF, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997;15:2981-95.
9. Siu LL, Tannock IF. Chemotherapy dose escalation: Case unproven. J Clin Oncol 1997;15:2765-8.
10. Mazza P, Tura S, Zinzani PL, Bocchis M, Gherlinzoni F, Pileri S, et al. A multicenter randomized study on aggressive non-Hodgkin's lymphomas: An updated follow-up. Proc Am Soc Clin Oncol 1993;12:362.
11. Gianni AM, Bregni M, Siena S, Brambilla C, DiNicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B cell lymphoma. N Engl J Med 1997;336:1290-7.
12. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coittier B, Brice P, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study of LNH 87-2. J Clin Oncol 1997;15:1131-7.
13. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
14. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-5.
15. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995;13:2483-9.
16. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
17. Haioun C, Lepage E, Gisselbrecht C, Coittier B, Bosly A, Dilly H, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 1994;12:2543-51.
18. Hagenbeek A, Verkonck L, Sonneveld P. CHOP chemotherapy versus autologous bone marrow transplantation in slowly responding patients with intermediate-and high-grade malignant non-Hodgkin's lymphoma. Results from a randomized phase III clinical trial in 294 patients. Blood 1993;82 (Suppl 1):332a.
19. Verdonck LF, van Putten WLJ, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995;332:1045-51.
20. Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy. A prospective randomized Italian multicenter study. J Clin Oncol 1996;14:534-42.
21. Rodenhuis S, Richel DJ, Wall vander E, Schornager JM, Baars JW, Koning CC, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet 1998;352:515-21.
22. Peters WP, Jones RB, Vrendenburgh J. A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996;15:121.
23. Chevreau C, Droz JP, Pico L, Biron P, Kerbrat P, Cure H, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors: Preliminary results of a French randomized trial. Eur Urol 1993;23:213-17.
24. Humblet Y, Symann M, Basly A. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 1987;5:1864-73.
25. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial. Lancet 1993;341:1051-4.
26. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649-56.
27. Burnett AK, Goldstone AH, Stevens RMF, Hann IM, Rees JK, Gray RG, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial. Lancet 1998;351:700-8.
28. Antman KH, Armitage JO, Horowitz MM, Rowlings PA. Autotransplants for breast cancer in North America. Proc Annu Meet Am Soc Clin Oncol 1994;13:A69.
29. Cannellos GP. Selection bias in trials of transplantation for metastatic breast cancer: Have we picked the apple before it was ripe? J Clin Oncol 1997;15:3169-70.
30. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997;15:3171-7.
31. Garcia-Carbonero R, Hindalgo M, Paz-Ares L, Calzas J, Gomez H, Guerra JA, et al. Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer. J Clin Oncol 1997;15:3178-84.
32. Gratwohl A, Hermans J, Baldomero H. Hematopoietic precursor cell transplants in Europe: Activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996;17:137-48.
33. Kumar L, Gulati SC. Peripheral stem-cell transplantation. Lancet 1995;346(Suppl):9.
34. Roberts MM, To LB, Gillis D, Mindy J, Rawling C, Ngo K, et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993;12:469-75.
35. Larsson K, Bjorkstrand B, Ljungman B. Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation.Support Care Cancer 1998;6:378-83.
36. Nemunaitis J, Buckner CD, Dorsey KS, Willis D, Meyer W, Applebaum F. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer. Am J Clin Oncol 1998;21:341-6.
37. Geisler CH, Hansen MM, Andersen NS, Broun P, Christensen LD, Dickmeiss E, et al. BEAM+autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single centre. Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatment. Eur J Haematol 1998;61:173-82.
38. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;1194-8.
39. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, et al. Effect of peripheral blood progenitor cells mobilised by filgastrim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-4.
40. Schwartzberg LS, Birch R, Hazelton B, Tauer KW, Lee P Jr, Altemose R, et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992;1:317-27.
41. Brandt SJ,Peters WP, Atwater SK, Kurtzberger J, Borowitz MJ, Jones RB, et al. Effect of recombinant human granulocyte-macrophage colony stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988;318:869-76.
42. Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-5.
43. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer trials. N Engl J Med 1991;324: 1773-8.
44. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - a Southwest Oncology Group Trial. J Clin Oncol 1998;16:48-55.
45. Moreau P, Milpied N, Rapp MJ, Morseau A, Bourdin S, Mahe MA, et al. Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: Long term follow up in 35 cases. Leuk Lymphoma 1998;30:313-24.
46. Moreau P, Fleury J, Brice P, Colombat P, Bouabdallah R, Lioure B, et al. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: Retrospective analysis of 158 cases from the French registry. Bone Marrow Transplant 1998;21:787-93.
47. Arranz R, Tomas JF, Gil-Fernandez JJ, Martinez Chamorro C, Granados E, et al. Autologous stem cell transplantation (ASCT) for poor prognosis Hodgkin's disease (HD): Comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998;21:779-86.
48. Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-40.